SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-020827
Filing Date
2024-05-07
Accepted
2024-05-07 06:28:21
Documents
15
Period of Report
2024-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20240507.htm   iXBRL 8-K 29593
2 EX-99.1 a991pressreleasedatedmay72.htm EX-99.1 70427
6 x4logoa.jpg GRAPHIC 4345
  Complete submission text file 0001628280-24-020827.txt   244716

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20240507.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20240507_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20240507_pre.xml EX-101.PRE 13583
18 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20240507_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 24919485
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)